QuickView for YDL103C;jsessionid=15F15BB478DC6C77651BC16CE76A6F8A;jsessionid=FA09DD4A5D65571BA1AD979499E356E2;jsessionid=5DB5107377C50D220B2B02849FAC3A0E;jsessionid=2766B9A4379564671E9BCB65AB596CAF;jsessionid=A06FF884E94C89B37D11661C0B1FCC3D;jsessionid=24B0659A24F02E71CB6C1E7FA42D2AE7;jsessionid=B68CE8DCF34293064419D2FC706EEE06;jsessionid=11450DD1F1ACB4DF3D8A0710E0522F4B;jsessionid=FC6619599CF8D7F8F485CBF60E5B9D2A;jsessionid=195C33B92613214314C72339F2A99309;jsessionid=9D1BE86943CF197E2C78016B436D9911;jsessionid=36720A8247B4706E30C586ADD67661BF (gene)

1. Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm.
2. Clinical Evaluation of Cystic Renal Masses With Bosniak Classification by Contrast-Enhanced Ultrasou…
3. Feasibility of Surveillance for Mucinous Cystic Neoplasm of the Pancreas: A Multi-Institutional Retr…
4. Clinicopathological and genetic characteristics of congenital cystic adenomatoid malformation of lun…
5. The added value of contrast-enhanced ultrasound in evaluation of indeterminate small solid renal mas…

There were no clinical trials for YDL103C;jsessionid=15F15BB478DC6C77651BC16CE76A6F8A;jsessionid=FA09DD4A5D65571BA1AD979499E356E2;jsessionid=5DB5107377C50D220B2B02849FAC3A0E;jsessionid=2766B9A4379564671E9BCB65AB596CAF;jsessionid=A06FF884E94C89B37D11661C0B1FCC3D;jsessionid=24B0659A24F02E71CB6C1E7FA42D2AE7;jsessionid=B68CE8DCF34293064419D2FC706EEE06;jsessionid=11450DD1F1ACB4DF3D8A0710E0522F4B;jsessionid=FC6619599CF8D7F8F485CBF60E5B9D2A;jsessionid=195C33B92613214314C72339F2A99309;jsessionid=9D1BE86943CF197E2C78016B436D9911;jsessionid=36720A8247B4706E30C586ADD67661BF